JP2013544797A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544797A5
JP2013544797A5 JP2013534982A JP2013534982A JP2013544797A5 JP 2013544797 A5 JP2013544797 A5 JP 2013544797A5 JP 2013534982 A JP2013534982 A JP 2013534982A JP 2013534982 A JP2013534982 A JP 2013534982A JP 2013544797 A5 JP2013544797 A5 JP 2013544797A5
Authority
JP
Japan
Prior art keywords
compound
salt
alkyl
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013534982A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013544797A (ja
JP5769326B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/056505 external-priority patent/WO2012054367A1/en
Publication of JP2013544797A publication Critical patent/JP2013544797A/ja
Publication of JP2013544797A5 publication Critical patent/JP2013544797A5/ja
Application granted granted Critical
Publication of JP5769326B2 publication Critical patent/JP5769326B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013534982A 2010-10-19 2011-10-17 Rhoキナーゼ阻害薬 Active JP5769326B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US39441410P 2010-10-19 2010-10-19
US61/394,414 2010-10-19
PCT/US2011/056505 WO2012054367A1 (en) 2010-10-19 2011-10-17 Rho kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013544797A JP2013544797A (ja) 2013-12-19
JP2013544797A5 true JP2013544797A5 (enExample) 2014-12-04
JP5769326B2 JP5769326B2 (ja) 2015-08-26

Family

ID=44898209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013534982A Active JP5769326B2 (ja) 2010-10-19 2011-10-17 Rhoキナーゼ阻害薬

Country Status (4)

Country Link
US (1) US9000154B2 (enExample)
EP (1) EP2630144B1 (enExample)
JP (1) JP5769326B2 (enExample)
WO (1) WO2012054367A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
JP5769326B2 (ja) 2010-10-19 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Rhoキナーゼ阻害薬
US9499553B2 (en) 2013-03-13 2016-11-22 Chugai Seiyaku Kabushiki Kaisha Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same
CN105492444B (zh) * 2013-07-02 2018-09-07 百时美施贵宝公司 作为rock抑制剂的三环吡啶-甲酰胺衍生物
EP3016950B1 (en) * 2013-07-02 2017-06-07 Bristol-Myers Squibb Company Tricyclic pyrido-carboxamide derivatives as rock inhibitors
WO2016112236A1 (en) * 2015-01-09 2016-07-14 Bristol-Myers Squibb Company Cyclic ureas as inhibitors of rock
EP3294871A1 (en) 2015-05-12 2018-03-21 Platod Combination of pharmacological and microfluidic features for improved platelets production
WO2020047229A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
IE914218A1 (en) 1991-09-11 1993-03-24 Mcneilab Inc Novel 4-arylpiperazines and 4-arylpiperidines
JPH11130751A (ja) 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd アミド化合物およびそれらの酸付加塩の標識化合物
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
BR0112395A (pt) * 2000-06-21 2003-07-08 Hoffmann La Roche Derivados de benzotiazol
WO2002044126A2 (en) 2000-11-28 2002-06-06 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
JPWO2002100833A1 (ja) 2001-06-12 2004-09-24 住友製薬株式会社 Rhoキナーゼ阻害剤
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2003321472A (ja) * 2002-02-26 2003-11-11 Takeda Chem Ind Ltd Grk阻害剤
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
EP1600442B1 (en) * 2003-02-26 2018-01-17 Msd K.K. Heteroarylcarbamoylbenzene derivative
JPWO2004101529A1 (ja) * 2003-05-19 2006-07-13 小野薬品工業株式会社 含窒素複素環化合物およびその医薬用途
FR2862965B1 (fr) 2003-11-27 2007-09-07 Merck Sante Sas Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides.
US8071603B2 (en) 2004-09-20 2011-12-06 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP1807390A4 (en) 2004-11-04 2008-07-02 Neurogen Corp ARYL ALKYL UREA AS CB1 ANTAGONISTS
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
WO2007008926A1 (en) 2005-07-11 2007-01-18 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
CA2664335C (en) 2006-09-20 2014-12-02 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2008053319A1 (en) 2006-10-30 2008-05-08 Pfizer Products Inc. Amide resorcinol compounds
EP2079694B1 (en) 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
CL2007003874A1 (es) 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
WO2008157330A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
EP2193119B1 (en) 2007-08-27 2014-01-01 Abbvie Deutschland GmbH & Co. KG 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
CA2697663A1 (en) 2007-08-30 2009-03-05 Takeda Pharmaceutical Company Limited Substituted pyrazole derivative
KR101573091B1 (ko) 2007-11-16 2015-11-30 리겔 파마슈티칼스, 인크. 대사성 장애를 위한 카르복스아미드, 술폰아미드 및 아민 화합물
WO2009119880A1 (en) 2008-03-26 2009-10-01 Takeda Pharmaceutical Company Limited Substituted pyrazole derivatives and use thereof
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
JP5769326B2 (ja) 2010-10-19 2015-08-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Rhoキナーゼ阻害薬

Similar Documents

Publication Publication Date Title
JP2013544797A5 (enExample)
JP2013530237A5 (enExample)
JP2018507877A5 (enExample)
JP2017509586A5 (enExample)
JP2016505010A5 (enExample)
JP2019518766A5 (enExample)
JP2012506368A5 (enExample)
JP2016505042A5 (enExample)
JP2020502049A5 (enExample)
JP2010536761A5 (enExample)
JP2016510033A5 (enExample)
JP2012502890A5 (enExample)
CN112074519A8 (zh) 作为rip1激酶抑制剂用于治疗e.g.肠易激综合征(ibs)的n-[4-氧代-2,3-二氢-1,5-苯并氧氮杂䓬-3-基]-5,6-二氢-4h-吡咯并[1,2-b]吡唑-2-甲酰胺衍生物和有关化合物
JP2009536620A5 (enExample)
JP2012502111A5 (enExample)
JP2017504635A5 (enExample)
JP2014139226A5 (enExample)
JP2008510770A5 (enExample)
JP2010504908A5 (enExample)
JP2016518328A5 (enExample)
JP2017525737A5 (enExample)
JP2011505347A (ja) Dna中のg−四重鎖領域と相互作用するナフタレンジイミド化合物
JP2014511891A5 (enExample)
JP2012515209A5 (enExample)
JP2018522033A5 (enExample)